Arginine, L-arginine, Arginine
Arginine is a basic protein, which is the main nitrogen carrier in the blood. The human body uses arginine to synthesize nitric oxide, which helps blood vessels relax and expand. This is important for regulating blood flow. Arginine can be used to treat a variety of health problems, but overconsumption can cause bone and skin disease.
- Origin: Plant Based, Animal Product, Synthetic
- Source: Milk, Eggs, Meat, Fish, Wheat Germs, Soybean, Beans, Chickpea, Peanuts, Walnuts, Hazelnut, Oatmeal, Spirulina Algae, pumpkin seeds, sunflower seeds
- Type: Amino Acid
- Age Range: Adults (18-60)
- Toxicity: May be toxic in high doses
- Outcomes: Energy and Mood, Anxiety
What are Arginine benefits?
Arginine is an amino acid that is important for various functions in the body, aids in healing, strengthens the immune system, and eliminates toxins from the body. In addition, it helps improve muscle performance by increasing lean mass gain and decreasing fatigue. This amino acid can be found in some foods, such as cheese, nuts, walnuts, beans, and cocoa, for example. It can be consumed in supplement form and is usually recommended for athletes, since this amino acid helps to decrease muscle fatigue and promote muscle mass gain. Cancer prevention and hair hydration are other benefits of this substance. So, be sure to check out the supplements your body needs through our test, in a few minutes you can start taking care of your health.
Table of relations
Published articles about Arginine and Anxiety
A Prospective, Randomized Double-blind, Placebo-controlled Study Of Safety And Efficacy Of A High-concentration Full-spectrum Extract Of Ashwagandha Root In Reducing Stress And Anxiety In Adults
600 mg of an ashwagandha extract ('full spectrum') for 60 days in persons with chronic mental stress was able to improve all tested parameters and reduced serum cortisol by 27.9%.
300 mg ashwagandha (1.5% withanolides) twice daily over the course of 8 weeks in persons with anxiety disorders also given counselling (placebo also given counselling) noted that supplementation was associated with a 56.5% reduction in anxiety symptoms as assessed by BAI while placebo only say a 30.5% reduction.
A Double-blind, Placebo-controlled Evaluation Of The Anxiolytic Efficacy Ff An Ethanolic Extract Of Withania Somnifera
Six weeks supplementation of Ashwagandha (250mg twice daily of the root extract) in persons with diagnosed generalized anxiety disorder (mixed anxiety and depression) noted significant improvements in both depression and anxiety symptoms. This study had a high dropout rate (18 out of 39 persons)
Randomized Placebo-controlled Adjunctive Study Of An Extract Of Withania Somnifera For Cognitive Dysfunction In Bipolar Disorder
In a randomized, double-blind, placebo-controlled trial, 60 subjects with bipolar disorder took an ashwagandha extract or placebo for 8 weeks. The subjects who took ashwagandha received 250 mg/d (standardized to a minimum of 8% withanolides and a maximum of 2% Withaferin A) for the first week, and 500 mg for the rest of the study, however, if the participants suspected adverse effects of ashwagandha, they were allowed to reduce their dose to 250 mg/d, which was the case with 3. The primary outcome was working memory as evaluated by an auditory 8 Digit-Span test. Compared with placebo, the ashwagandha group saw a small, statistically significant improvement in the span backward portion, but not for span forward. The participants also performed the flanker test and the results favored the ashwagandha group but were only statistically significant for the neutral condition. Results for tests of executive function and processing speed were ambiguous and not statistically significant. The researchers also evaluated affective symptoms and possibly found reductions in depression and mania, but not anxiety, though statistical tests weren't performed for these. The only adverse event that seemed to be higher in the ashwagandha group was diarrhea in 5 participants compared with 1 in the placebo group.
In a randomized, double-blind, placebo-controlled study, 86 patients with Generalized Anxiety Disorder were assigned to take either placebo or 12 g of ashwagandha sugar granules (unclear dose of ashwagandha and its chemicals) daily for 60 days. The primary and only outcome was the symptoms on the Hamilton Anxiety Rating Scale. Compared with the placebo group, the ashwaganda group saw a statistically significant improvement in 'anxious mood' and 'tension', while the differences weren't statistically significant for the other symptoms. However, the reduction in every symptom was greater for the ashwagandha group than the placebo group. 58.13% of patients in the ashwagandha group were evaluated as seeing a moderate improvement, 39.53% saw a mild improvement, and 2.32% were unchanged. In the placebo group, this was 0, 81.39, and 18.6%, respectively.
A Standardized Withania Somnifera Extract Significantly Reduces Stress-Related Parameters in Chronically Stressed Humans: A Double-Blind, Randomized, Placebo-Controlled Study
In a randomized, double-blind, placebo-controlled trial, 130 participants with an anxiety disorder were assigned to take 125 mg, 250 mg, or 500 mg of ashwagandha extract containing a minimum of 8% withanolide glycosides, 32% oligosaccharides, and a maximum of 2% withaferin A for 60 days. 32 participants dropped out, with more dropouts in the placebo group. While the placebo group saw no notable changes, the ashwaganda groups all saw statistically significant improvements compared with the placebo group in stress/anxiety, fatigue, flushing, perspiration, loss of appetite, headache and muscle pain, feelings of impending doom, palpitations, dry mouth, sleeplessness, forgetfulness, irritability, and inability to concentrate. The 250 mg and 500 mg groups seemed to be somewhat more potent than the 125 mg group for stress/anxiety, fatigue and inability to concentrate. Serum cortisol, CRP and serum VLDL-C, and blood pressure were statistically significantly reduced compared with placebo in all ashwagandha groups, and DHEAS was significantly increased. Fasting blood glucose, total serum cholesterol, serum triglycerides, LDL-C, and HDL-C were improved in the 250 mg and 500 mg groups compared with placebo, and the 500 mg group was significantly lower than the 125 mg group for all but CRP and fasting blood glucose.
Adaptogenic And Anxiolytic Effects Of Ashwagandha Root Extract In Healthy Adults: A Double-blind, Randomized, Placebo-controlled Clinical Study
In a randomized, double-blind, placebo-controlled trial, 60 healthy participants who reported high levels of stress were allocated to take a placebo, 250 mg of an ashwagandha extract or 600 mg of an extract for 8 weeks. The extract was derived from roots and was standardized to 5% withanolides. There was a statistically significantly greater reduction in score on the Perceived Stress Scale in both ashwagandha groups than for placebo, though the difference was small/modest. The reduction in serum cortisol in the ashwagandha groups was notably greater than for placebo, and the reduction in score on the Hamilton Anxiety Rating Scale (HAM-A) was statistically significantly greater for the high dose group but not the low-dose group. The improvements in sleep quality were greater for both ashwagandha groups than for placebo, and the greatest for the high dose group. Notable differences between groups for adverse events weren't found.
Efficacy And Safety Of Ashwagandha (Withania Somnifera) Root Extract In Insomnia And Anxiety: A Double-blind, Randomized, Placebo-controlled Study
In a randomized, double-blind, placebo-controlled trial, 60 participants who had been diagnosed with insomnia were allocated to take placebo or 300 mg of an ashwagandha extract derived from roots with 5% withanolides for 10 weeks. The primary outcome was sleep onset latency, as assessed by actigraphy. At the end of 10 weeks, sleep onset latency had considerably improved in both groups, with a somewhat greater improvement in the ashwagandha group that was statistically significant compared with the placebo. The same was the case for sleep efficiency, and the greater improvement in the ashwagandha group was almost statistically significant for total sleep time and time awake after sleep onset (p=0.076). Sleep quality on The Pittsburgh Sleep Quality Index (PSQI) was improved more in the ashwagandha group, and the difference was statistically significant, and as was the score on the Hamilton Anxiety Rating Scale (HAM-A).
An Investigation Into The Stress-relieving And Pharmacological Actions Of An Ashwagandha (Withania Somnifera) Extract: A Randomized, Double-blind, Placebo-controlled Study
In a randomized, double-blind, placebo-controlled trial, 60 adults with mild anxiety were allocated to take placebo or 240 mg of a broad spectrum ashwagandha extract containing 35% Withanolide Glycosides daily for 60 days. The primary outcome was anxiety, as assessed by the Hamilton Anxiety Rating Scale (HAM-A). Score on the Depression, Anxiety, Stress Scale-21 (DASS-21) was claimed to be the second primary outcome. The HAM-A was improved significantly more in the ashwagandha group than the placebo group and DASS-21saw a non-significantly greater improvement in the ashwagandha group that was fairly notable. There was a greater reduction in cortisol and DHEA-S in the ashwagandha group that was statistically significant between groups. Testosterone was unchanged for females and was somewhat increased in males, which was statistically significant within-group but not between groups.
Double-blind, Controlled, Crossover Trial Of Inositol Versus Fluvoxamine For The Treatment Of Panic Disorder
18g of inositol taken daily for one month in persons with panic disorder was associated with a significant reduction in panic attack symptoms (more potent than the reference drug of fluvoxamine) and anxiety symptoms (comparable in potency)
12g of inositol daily for a period of 4 weeks is associated with reductions in symptoms of panic disorder and anxiety, particularly a reduction in agoraphobia.
Supplementation of 18g inositol in persons with binge eating disorder or bulimia was effective in reducing symptoms of binge eating as well as both anxiety and depression. The lone male patient did not respond to treatment.
In a placebo controlled crossover design, supplementation of 18g inositol daily for six weeks in persons with obsessive compulsive disorder was able to reduce symptoms as assessed by the Yale-Brown Obsessive Compulsive Scale (to 76% of baseline; placebo down to 94%)
Kava-kava Extract WS 1490 Versus Placebo In Anxiety Disorders--a Randomized Placebo-controlled 25-week Outpatient Trial
101 patients suffering from non-psychotic anxiety using Kava (WS 1490 extract) over 25 weeks noted statistically significant benefits starting after week 8.
Clinical Efficacy Of Kava Extract WS 1490 In Sleep Disturbances Associated With Anxiety Disorders. Results Of A Multicenter, Randomized, Placebo-controlled, Double-blind Clinical Trial
In 61 persons with non-psychotic anxiety, Kava was more effective than placebo at improving sleep (both quality and recuperative effects) and reducing anxiety at 200mg of WS 1490 daily over 4 weeks
150mg of an extract of Kava (WS 1490, aka. Laitan) in persons with non-psychotic anxiety with a total HAMA score of greater than 18 was significantly more effective than placebo in reducing the HAMA rating on anxiety when assessed by a per-protocol analysis. However, significant differences existed between groups at baseline in regards to HAMA.
The Kava Anxiety Depression Spectrum Study (KADSS): A Randomized, Placebo-controlled Crossover Trial Using An Aqueous Extract Of Piper Methysticum
Over a period of 3 weeks active treatment (one week run in phase),16g of Kava standardized to 250mg of activa kavalactones daily (2/5ths in the morning and afternoon, 1/5th in the evening) as an aqueous extract was able to exert anxiolytic and anti-depressive actions in persons with at least one month of higher but stable anxiety levels. No hepatotoxic signs noted via clinical assessment, liver enzymes not measured.
Efficacy Of Kava-kava In The Treatment Of Non-psychotic Anxiety, Following Pretreatment With Benzodiazepines
This study model used low dose Kava (WS 1490 extract) at 50mg and worked up to 300mg while concurrently reducing pharmaceutical usage (benzodiazepeine) from 50% of the normal dose when Kava was introduced, tapering off at 2 weeks for anotehr 3 weeks of Kava treatment. Kava showed efficacy in reducing anxiety and was an effective substitute for benzodiazepines, with statistically better results (relative to placebo, which tapered off and got nothing to replace it with) after 8 days.
Treatment Of Anxiety, Tension And Restlessness States With Kava Special Extract WS 1490 In General Practice: A Randomized Placebo-controlled Double-blind Multicenter Trial
150mg of Kava WS 1490 extract daily in persons suffering from neurotic anxiety noted significant reductions in anxiety as assessed by the Anxiety Status Inventory (ASI) after 4 weeks of treatment. No effect on liver enzymes (Alkaline Phosphatase, y-GT, GOT, GPT) in this trial.
37 adults with DSM-IV diagnosed Generalized Anxiety Disorder had Kava fail to demonstrate itself better than placebo, although both helped
A meta-analysis of 11 studies using Kava relative to placebo noted that Kava was significantly more effective than placebo at reducing anxiety.
Curcumin For The Treatment Of Major Depression: A Randomised, Double-blind, Placebo Controlled Study
A total of 56 individuals with MDD were treated with 500 mg of BCM-95 curcumin (twice daily) or placebo for eight weeks. The primary measure was the IDS-SR30. Secondary outcomes included IDS-SR30 factor scores and the STAI. After eight weeks, The curcumin group experienced a 33.1% decrease in IDS-SR30 scores, a 19% decrease in STAI-S scores and a 14.8% decrease in STAI-T scores.
An Investigation Of The Effects Of Curcumin On Anxiety And Depression In Obese Individuals: A Randomized Controlled Trial
Thirty-five subjects (mean age: 38.37 ±11.51; 83% females were a part of the trial. Participants were given either capsules containing a mix of 500 mg of C3 Complex, along with 5 mg of bioperine or placebo capsules that were of the exact size and shape, which only contained 5 mg of bioperine. The subjects were required to take two capsules of curcumin a day (1 g) or two capsules of placebo a day for thirty days. The treatment period lasted for thirty days after which the patients were required to switch over to the alternative treatment following a 2-week wash-out interval between the regimens. Psychometric tests such as the Beck Anxiety Inventory (BAI) and Beck Depression Inventory (BDI) were administered to each participant at baseline, week 4, 6, and 10 of the trial. The trial found that curcumin had no significant effect on the mean BDI score for the overall study population when compared to placebo (P=0.7), however, it was associated with a significant reduction on the mean BAI score when compared to the placebo group (P=0.03).
Efficacy Of Curcumin, And A Saffron/curcumin Combination For The Treatment Of Major Depression: A Randomised, Double-blind, Placebo-controlled Study
This was a 12-week randomized, double-blind, placebo-controlled trial on males and females 18-65 years of age who met the DSM-IV criteria for major depressive disorder and who had an Inventory of Depressive Symptomatology self-rated version (IDS-SR30) score of at least 18. The primary outcome measures were the IDS-SR30 scores and the secondary outcomes were STAI-T and STAI-S scores. The participants were randomized to four groups: The remaining participants were randomized to four groups with the following capsules: placebo, low-dose curcumin containing 250 milligrams of the patented curcumin BCM-95 (LDC), high-dose curcumin containing 500 milligrams of BCM-95 (HDC), and low-dose curcumin/ saffron combination, containing 250 milligrams of BCM-95 and 15 milligrams of a saffron extract(LDC+S). After 12 weeks, the combined curcumin group experienced a 33.1% reduction in IDS-SR30 scores, a 19.0% reduction in STAI-S scores, and a 16.5% reduction in STAI-T scores.
Investigation Of The Efficacy Of Adjunctive Therapy With Bioavailability-boosted Curcuminoids In Major Depressive Disorder
In an open-label trial, 111 participants with major depression were assigned to take standard antidepressant therapy or antidepressants with 1000 mg of curcuminoids and 10 mg piperine daily for 6 weeks. By the end of the trial, 26% of participants had dropped out of the trial, with a somewhat higher rate in the curcuminoid group. The participants were measured for symptoms of depression and anxiety by the Beck-II inventory and the Hospital Anxiety and Depression Scale (HADS). For Beck-II, the reduction in depression was modestly larger for curcuminoids than for placebo and statistically significant in comparison. The same was the case for HADS for both anxiety and depression.
Evaluating Therapeutic Effect In Symptoms Of Moderate-to-severe Premenstrual Syndrome With Vitex Agnus Castus (BNO 1095) In Chinese Women
4mg of BNO 1095 (10:1 concentrated ethanolic extract of the plant) daily appears to reduce a variety of symptoms in Chinese women suffering moderate to severe PMS symptoms when taken daily.
The aroma of lavender was more effective than orange, music, or nothing in reducing anxiety and improving mood state in the setting of a dental office lobby.
The Effects Of Lavender Scent On Dental Patient Anxiety Levels: A Cluster Randomised-controlled Trial
In a dental office setting, the aroma of lavender was associated with less acute anxiety although it did not appear to affect general and future predicted anxiety
Phase II Trial On The Effects Of Silexan In Patients With Neurasthenia, Post-traumatic Stress Disorder Or Somatization Disorder
80mg of Silexan for 6 weeks in persons with anxiety related disorders (neurasthenia, PTSD, and somatization disorder) was associated with a reduction of anxiety and restlessness like symptoms (associated with neurasthenia) relative to baseline in more than half of the sample.
A Multi-center, Double-blind, Randomised Study Of The Lavender Oil Preparation Silexan In Comparison To Lorazepam For Generalized Anxiety Disorder
80mg of lavender oil (Silexan) is able to reduce anxiety over 6 weeks as effectively as the active control lorazepam at 500mg without sedation; no placebo control.
Silexan, An Orally Administered Lavandula Oil Preparation, Is Effective In The Treatment Of 'subsyndromal' Anxiety Disorder: A Randomized, Double-blind, Placebo Controlled Trial
10 weeks ingestion of 80mg Silexan (Lavender oil) is able to reduce anxiety and, vicariously through that, improve sleep in persons with minor anxiety
The Effect Of Vitamin D Supplement Consumption On Premenstrual Syndrome In Vitamin D-Deficient Young Girls: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial
In a randomized, double-blind, placebo-controlled trial, 130 women with premenstrual syndrome and vitamin D deficiency ( serum 25-(OH)-D <20 ng/mL) were allocated to take 2,000 IU of vitamin D or placebo every other day for 12 weeks. At the end of 12 weeks, symptom score on the Premenstrual Symptoms Screening Tool (PSST) questionnaire was improved for most outcomes in both groups, with no statistically significantly greater improvements in either group. It should be noted that the scores weren't very severe to begin with.
Evaluating The Effects Of Vitamin D And Vitamin E Supplement On Premenstrual Syndrome: A Randomized, Double-blind, Controlled Trial
In a randomized, double-blind, placebo-controlled trial, 28 women with premenstrual syndrome were allocated to take 200 mg of vitamin D or placebo daily for 2 months. There was a slightly greater improvement in overall symptoms in the vitamin D group, but the difference between groups wasn't statistically significant. The depression score saw a more notable improvement compared with the others, though it's unclear if the difference was statistically significant.
Vitamin D Supplementation For Premenstrual Syndrome-Related Mood Disorders In Adolescents With Severe Hypovitaminosis D
In a randomized, double-blind, placebo-controlled trial, 158 girls with premenstrual syndrome and severe vitamin D deficiency (≤ 10 ng/mL) were allocated to 200,000 IU followed by 25,000 IU every 2 weeks for 4 months. Anxiety, irritiability, sadness, and relationship disturbances were reduced considerably after 4 months in the vitamin D group but not the placebo group, and 'crying easily was also reduced but less so. There was no notable difference between groups in overall adverse events.
Effect Of Zinc Sulfate Supplementation On Premenstrual Syndrome And Health-related Quality Of Life: Clinical Randomized Controlled Trial
In a randomized, double-blind, placebo-controlled trial, 142 women with PMS were allocated to either 220 mg of zinc sulfate (50 mg of elemental zinc) or placebo daily from the 16th day of each menstrual cycle to the 2nd day of the next for 3 months. On the Premenstrual Symptoms Screening Tool, anger/irritability, anxiety/tension, depressed mood, decreased interest in world activities, decreased interest in-home activities, difficulty concentrating, fatigue, insomnia, hypersomnia, feeling overwhelmed, and physical symptoms all improved in the zinc group more than the placebo group, the difference being statistically significant. In contrast, tearfulness wasn't improved. The improvement in work efficiency, relationship with coworkers, relationships with family, social life activities, and home responsibilities were all improved more in the zinc group than the placebo group, the difference being statistically significant. The improvement tended to increase each month, which likely reflects zinc status improving each month. On the 12-item Short-Form Health Survey Questionnaire, there was a modest improvement for both physical and psychological symptoms which was statistically significant compared with placebo.
Published articles about Arginine and Preventive Immunity
Immunity, as expressed by T-cell activation, and NK cell activation as assessed by CD56+ expression, were enhanced after 96 hours of using ashwagandha at 12 mL/day, in two divided dosages (3:1 ratio of root extract to volume)
Salivary Secretory Immunoglobulin A Secretion Increases After 4-weeks Ingestion Of Chlorella-derived Multicomponent Supplement In Humans: A Randomized Cross Over Study
Salivary concentrations of Immunoglobulin A were significantly increased with 6g Chlorella daily over 4 weeks in otherwise healthy adult men
Anxiety is the body's natural response to stress. It's a feeling of fear or apprehension about what's to come. It can be triggered by a specific situation and not last long - which is very common and ok - or it can be a generalized disorder (which is considered a illness) that can bring harm to everyday life and also cause other conditions like depression.
Table of negative interactions
Related videos about Arginine
- ^ a b Figueroa A, et al. Watermelon extract supplementation reduces ankle blood pressure and carotid augmentation index in obese adults with prehypertension or hypertension. Am J Hypertens. (2012)
- ^ a b Corpas E, et al. Oral arginine-lysine does not increase growth hormone or insulin-like growth factor-I in old men. J Gerontol. (1993)
- ^ a b Buford BN, Koch AJ. Glycine-arginine-alpha-ketoisocaproic acid improves performance of repeated cycling sprints. Med Sci Sports Exerc. (2004)
- ^ a b Stevens BR, et al. High-intensity dynamic human muscle performance enhanced by a metabolic intervention. Med Sci Sports Exerc. (2000)
- ^ Wu G, Morris SM Jr. Arginine metabolism: nitric oxide and beyond. Biochem J. (1998)
- ^ Arginine metabolism in mammals.
- ^ Malinauskas BM, et al. Supplements of interest for sport-related injury and sources of supplement information among college athletes. Adv Med Sci. (2007)
- ^ Tharakan JF, et al. Adaptation to a long term (4 weeks) arginine- and precursor (glutamate, proline and aspartate)-free diet. Clin Nutr. (2008)
- ^ a b c de Jonge WJ, et al. Overexpression of arginase I in enterocytes of transgenic mice elicits a selective arginine deficiency and affects skin, muscle, and lymphoid development. Am J Clin Nutr. (2002)
- ^ de Jonge WJ, et al. Arginine deficiency affects early B cell maturation and lymphoid organ development in transgenic mice. J Clin Invest. (2002)
- ^ de Jonge WJ, et al. Overexpression of arginase alters circulating and tissue amino acids and guanidino compounds and affects neuromotor behavior in mice. J Nutr. (2001)
- ^ Kwikkers KL, et al. Effect of arginine deficiency on arginine-dependent post-translational protein modifications in mice. Br J Nutr. (2005)
- ^ a b Morris CR, et al. Dysregulated arginine metabolism, hemolysis-associated pulmonary hypertension, and mortality in sickle cell disease. JAMA. (2005)
- ^ a b Diabetes-induced Coronary Vascular Dysfunction Involves Increased Arginase Activity.
- ^ Schramm L, et al. L-arginine deficiency and supplementation in experimental acute renal failure and in human kidney transplantation. Kidney Int. (2002)
- ^ a b Adverse Gastrointestinal Effects of Arginine and Related Amino Acids.
- ^ Morris SM Jr. Recent advances in arginine metabolism. Curr Opin Clin Nutr Metab Care. (2004)
- ^ De Bandt JP, et al. Metabolism of ornithine, alpha-ketoglutarate and arginine in isolated perfused rat liver. Br J Nutr. (1995)
- ^ Curis E, et al. Almost all about citrulline in mammals. Amino Acids. (2005)
- ^ Plasma arginine and citrulline kinetics in adults given adequate and arginine-free diets.
- ^ a b c Häberle J, et al. Suggested guidelines for the diagnosis and management of urea cycle disorders. Orphanet J Rare Dis. (2012)
- ^ Bommarius AS, Makryaleas K, Drauz K. An enzymatic route to L-ornithine from L-arginine–activation and stabilization studies on L-arginase. Biomed Biochim Acta. (1991)
- ^ Bommarius AS, Drauz K. An enzymatic route to L-ornithine from arginine–activation, selectivity and stabilization of L-arginase. Bioorg Med Chem. (1994)
- ^ a b Targeted cellular metabolism for cancer chemotherapy with recombinant arginine-degrading enzymes.
- ^ Dai Z, et al. Nitric oxide and energy metabolism in mammals. Biofactors. (2013)
- ^ a b Molderings GJ, Haenisch B. Agmatine (decarboxylated L-arginine): physiological role and therapeutic potential. Pharmacol Ther. (2012)
- ^ Regunathan S, Reis DJ. Characterization of arginine decarboxylase in rat brain and liver: distinction from ornithine decarboxylase. J Neurochem. (2000)
- ^ Raasch W, et al. Agmatine, the bacterial amine, is widely distributed in mammalian tissues. Life Sci. (1995)
- ^ Raasch W, et al. Agmatine is widely and unequally distributed in rat organs. Ann N Y Acad Sci. (1995)
- ^ Li G, et al. Agmatine: an endogenous clonidine-displacing substance in the brain. Science. (1994)
- ^ a b c d e f g Bode-Böger SM, et al. L-arginine-induced vasodilation in healthy humans: pharmacokinetic-pharmacodynamic relationship. Br J Clin Pharmacol. (1998)
- ^ a b c d Tangphao O, et al. Pharmacokinetics of intravenous and oral L-arginine in normal volunteers. Br J Clin Pharmacol. (1999)
- ^ White MF, Christensen HN. The two-way flux of cationic amino acids across the plasma membrane of mammalian cells is largely explained by a single transport system. J Biol Chem. (1982)
- ^ White MF, Gazzola GC, Christensen HN. Cationic amino acid transport into cultured animal cells. I. Influx into cultured human fibroblasts. J Biol Chem. (1982)
- ^ MacLeod CL. Regulation of cationic amino acid transporter (CAT) gene expression. Biochem Soc Trans. (1996)
- ^ MacLeod CL, Finley KD, Kakuda DK. y(+)-type cationic amino acid transport: expression and regulation of the mCAT genes. J Exp Biol. (1994)
- ^ Identification and Characterization of a Membrane Protein (y+L Amino Acid Transporter-1) That Associates with 4F2hc to Encode the Amino Acid Transport Activity y+L A CANDIDATE GENE FOR LYSINURIC PROTEIN INTOLERANCE.
- ^ Verrey F, et al. New glycoprotein-associated amino acid transporters. J Membr Biol. (1999)
- ^ a b c Dall’Asta V, et al. Arginine transport through system y(+)L in cultured human fibroblasts: normal phenotype of cells from LPI subjects. Am J Physiol Cell Physiol. (2000)
- ^ a b c d e Collier SR, Casey DP, Kanaley JA. Growth hormone responses to varying doses of oral arginine. Growth Horm IGF Res. (2005)
- ^ a b Jabecka A, et al. Oral L-arginine supplementation in patients with mild arterial hypertension and its effect on plasma level of asymmetric dimethylarginine, L-citruline, L-arginine and antioxidant status. Eur Rev Med Pharmacol Sci. (2012)
- ^ a b c d e Wilson AM, et al. L-arginine supplementation in peripheral arterial disease: no benefit and possible harm. Circulation. (2007)
- ^ a b Teerlink T. Letter by Teerlink regarding article, “L-arginine supplementation in peripheral arterial disease: no benefit and possible harm”. Circulation. (2008)
- ^ Bliss TV, Collingridge GL. A synaptic model of memory: long-term potentiation in the hippocampus. Nature. (1993)
- ^ Hawkins RD, Kandel ER, Siegelbaum SA. Learning to modulate transmitter release: themes and variations in synaptic plasticity. Annu Rev Neurosci. (1993)
- ^ a b Huang EP. Synaptic plasticity: a role for nitric oxide in LTP. Curr Biol. (1997)
- ^ a b Schuman EM, Madison DV. A requirement for the intercellular messenger nitric oxide in long-term potentiation. Science. (1991)
- ^ Arancio O, et al. Nitric oxide acts directly in the presynaptic neuron to produce long-term potentiation in cultured hippocampal neurons. Cell. (1996)
- ^ Bartus K, Pigott B, Garthwaite J. Cellular targets of nitric oxide in the hippocampus. PLoS One. (2013)
- ^ a b O’Dell TJ, et al. Endothelial NOS and the blockade of LTP by NOS inhibitors in mice lacking neuronal NOS. Science. (1994)
- ^ Endothelial nitric oxide synthase localized to hippocampal pyramidal cells: implications for synaptic plasticity.
- ^ a b c Son H, et al. Long-term potentiation is reduced in mice that are doubly mutant in endothelial and neuronal nitric oxide synthase. Cell. (1996)
- ^ Sakoda T, et al. Myristoylation of endothelial cell nitric oxide synthase is important for extracellular release of nitric oxide. Mol Cell Biochem. (1995)
- ^ Kantor DB, et al. A role for endothelial NO synthase in LTP revealed by adenovirus-mediated inhibition and rescue. Science. (1996)
- ^ Lameu C, de Camargo AC, Faria M. L-arginine signalling potential in the brain: the peripheral gets central. Recent Pat CNS Drug Discov. (2009)
- ^ Flam BR, Eichler DC, Solomonson LP. Endothelial nitric oxide production is tightly coupled to the citrulline-NO cycle. Nitric Oxide. (2007)
- ^ Xie L, Gross SS. Argininosuccinate synthetase overexpression in vascular smooth muscle cells potentiates immunostimulant-induced NO production. J Biol Chem. (1997)
- ^ Husson A, et al. Argininosuccinate synthetase from the urea cycle to the citrulline-NO cycle. Eur J Biochem. (2003)
- ^ Matarredona ER, et al. Nitric oxide synthesis inhibition increases proliferation of neural precursors isolated from the postnatal mouse subventricular zone. Brain Res. (2004)
- ^ Stoop R, Poo MM. Synaptic modulation by neurotrophic factors. Prog Brain Res. (1996)
- ^ Lo DC. Neurotrophic factors and synaptic plasticity. Neuron. (1995)
- ^ Hsieh HY, et al. Nitric oxide regulates BDNF release from nodose ganglion neurons in a pattern-dependent and cGMP-independent manner. J Neurosci Res. (2010)
- ^ Lameu C, et al. Interactions between the NO-citrulline cycle and brain-derived neurotrophic factor in differentiation of neural stem cells. J Biol Chem. (2012)
- ^ Kirschbaum C, Pirke KM, Hellhammer DH. The ‘Trier Social Stress Test’–a tool for investigating psychobiological stress responses in a laboratory setting. Neuropsychobiology. (1993)
- ^ a b Jezova D, et al. Subchronic treatment with amino acid mixture of L-lysine and L-arginine modifies neuroendocrine activation during psychosocial stress in subjects with high trait anxiety. Nutr Neurosci. (2005)
- ^ Jezova D, et al. High trait anxiety in healthy subjects is associated with low neuroendocrine activity during psychosocial stress. Prog Neuropsychopharmacol Biol Psychiatry. (2004)
- ^ Smriga M, et al. Oral treatment with L-lysine and L-arginine reduces anxiety and basal cortisol levels in healthy humans. Biomed Res. (2007)
- ^ Dietary L-Lysine Deficiency Increases Stress-Induced Anxiety and Fecal Excretion in Rats.
- ^ Lysine fortiﬁcation reduces anxiety and lessens stress in family members in economically weak communities in northwest Syria.
- ^ Chang YF, Gao XM. L-lysine is a barbiturate-like anticonvulsant and modulator of the benzodiazepine receptor. Neurochem Res. (1995)
- ^ Hasler WL. Lysine as a serotonin receptor antagonist: using the diet to modulate gut function. Gastroenterology. (2004)
- ^ Smriga M, Torii K. L-Lysine acts like a partial serotonin receptor 4 antagonist and inhibits serotonin-mediated intestinal pathologies and anxiety in rats. Proc Natl Acad Sci U S A. (2003)
- ^ Smriga M, Torii K. Prolonged treatment with L-lysine and L-arginine reduces stress-induced anxiety in an elevated plus maze. Nutr Neurosci. (2003)
- ^ Joung HY, et al. The differential role of NOS inhibitors on stress-induced anxiety and neuroendocrine alterations in the rat. Behav Brain Res. (2012)
- ^ Malinski T. Nitric oxide and nitroxidative stress in Alzheimer’s disease. J Alzheimers Dis. (2007)
- ^ McCann SM, et al. The nitric oxide theory of aging revisited. Ann N Y Acad Sci. (2005)
- ^ a b Calabrese V, et al. Nitric oxide in the central nervous system: neuroprotection versus neurotoxicity. Nat Rev Neurosci. (2007)
- ^ Rushaidhi M, et al. Aging affects L-arginine and its metabolites in memory-associated brain structures at the tissue and synaptoneurosome levels. Neuroscience. (2012)
- ^ Liu P, Jing Y, Zhang H. Age-related changes in arginine and its metabolites in memory-associated brain structures. Neuroscience. (2009)
- ^ Neural plasticity in the ageing brain.
- ^ Greenwood PM. Functional plasticity in cognitive aging: review and hypothesis. Neuropsychology. (2007)
- ^ a b Stuehr DJ. Structure-function aspects in the nitric oxide synthases. Annu Rev Pharmacol Toxicol. (1997)
- ^ Charles IG, et al. Expression of human nitric oxide synthase isozymes. Methods Enzymol. (1996)
- ^ Casas JP, et al. Endothelial nitric oxide synthase gene polymorphisms and cardiovascular disease: a HuGE review. Am J Epidemiol. (2006)
- ^ Griffith OW, Stuehr DJ. Nitric oxide synthases: properties and catalytic mechanism. Annu Rev Physiol. (1995)
- ^ Marletta MA. Nitric oxide synthase structure and mechanism. J Biol Chem. (1993)
- ^ Masters BS. Nitric oxide synthases: why so complex. Annu Rev Nutr. (1994)
- ^ Mayer B, et al. Brain nitric oxide synthase is a biopterin- and flavin-containing multi-functional oxido-reductase. FEBS Lett. (1991)
- ^ Hevel JM, White KA, Marletta MA. Purification of the inducible murine macrophage nitric oxide synthase. Identification as a flavoprotein. J Biol Chem. (1991)
- ^ Stuehr DJ, et al. Purification and characterization of the cytokine-induced macrophage nitric oxide synthase: an FAD- and FMN-containing flavoprotein. Proc Natl Acad Sci U S A. (1991)
- ^ Mayer B, Hemmens B. Biosynthesis and action of nitric oxide in mammalian cells. Trends Biochem Sci. (1997)
- ^ Ghosh DK, Abu-Soud HM, Stuehr DJ. Reconstitution of the second step in NO synthesis using the isolated oxygenase and reductase domains of macrophage NO synthase. Biochemistry. (1995)
- ^ Lekakis JP, et al. Oral L-arginine improves endothelial dysfunction in patients with essential hypertension. Int J Cardiol. (2002)
- ^ L-Arginine and Atherothrombosis.
- ^ a b Lucotti P, et al. Beneficial effects of a long-term oral L-arginine treatment added to a hypocaloric diet and exercise training program in obese, insulin-resistant type 2 diabetic patients. Am J Physiol Endocrinol Metab. (2006)
- ^ a b c d e f Acute L-arginine supplementation reduces the O2 cost of moderate-intensity exercise and enhances high-intensity exercise tolerance.
- ^ a b Fahs CA, Heffernan KS, Fernhall B. Hemodynamic and vascular response to resistance exercise with L-arginine. Med Sci Sports Exerc. (2009)
- ^ a b c Tang JE, et al. Bolus arginine supplementation affects neither muscle blood flow nor muscle protein synthesis in young men at rest or after resistance exercise. J Nutr. (2011)
- ^ a b c Alvares TS, et al. Acute l-arginine supplementation increases muscle blood volume but not strength performance. Appl Physiol Nutr Metab. (2012)
- ^ Durante W, Johnson FK, Johnson RA. Arginase: a critical regulator of nitric oxide synthesis and vascular function. Clin Exp Pharmacol Physiol. (2007)
- ^ Baydoun AR, et al. Substrate-dependent regulation of intracellular amino acid concentrations in cultured bovine aortic endothelial cells. Biochem Biophys Res Commun. (1990)
- ^ Palmer RM, Ashton DS, Moncada S. Vascular endothelial cells synthesize nitric oxide from L-arginine. Nature. (1988)
- ^ Cardounel AJ, et al. Evidence for the pathophysiological role of endogenous methylarginines in regulation of endothelial NO production and vascular function. J Biol Chem. (2007)
- ^ a b Hardy TA, May JM. Coordinate regulation of L-arginine uptake and nitric oxide synthase activity in cultured endothelial cells. Free Radic Biol Med. (2002)
- ^ a b Bode-Böger SM, Scalera F, Ignarro LJ. The L-arginine paradox: Importance of the L-arginine/asymmetrical dimethylarginine ratio. Pharmacol Ther. (2007)
- ^ a b Shin S, Mohan S, Fung HL. Intracellular L-arginine concentration does not determine NO production in endothelial cells: implications on the “L-arginine paradox”. Biochem Biophys Res Commun. (2011)
- ^ a b c Liu TH, et al. No effect of short-term arginine supplementation on nitric oxide production, metabolism and performance in intermittent exercise in athletes. J Nutr Biochem. (2009)
- ^ Tsukahara H, Gordienko DV, Goligorsky MS. Continuous monitoring of nitric oxide release from human umbilical vein endothelial cells. Biochem Biophys Res Commun. (1993)
- ^ a b Joshi MS, et al. Receptor-mediated activation of nitric oxide synthesis by arginine in endothelial cells. Proc Natl Acad Sci U S A. (2007)
- ^ a b McDonald KK, et al. A caveolar complex between the cationic amino acid transporter 1 and endothelial nitric-oxide synthase may explain the “arginine paradox”. J Biol Chem. (1997)
- ^ Zani BG, Bohlen HG. Transport of extracellular l-arginine via cationic amino acid transporter is required during in vivo endothelial nitric oxide production. Am J Physiol Heart Circ Physiol. (2005)
- ^ Kone BC. Protein-protein interactions controlling nitric oxide synthases. Acta Physiol Scand. (2000)
- ^ a b Vallance P, et al. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet. (1992)
- ^ a b Böger RH, et al. Restoring vascular nitric oxide formation by L-arginine improves the symptoms of intermittent claudication in patients with peripheral arterial occlusive disease. J Am Coll Cardiol. (1998)
- ^ a b Mittermayer F, et al. Asymmetric dimethylarginine predicts major adverse cardiovascular events in patients with advanced peripheral artery disease. Arterioscler Thromb Vasc Biol. (2006)
- ^ ADMA, Endothelial Progenitor Cells, and Cardiovascular Risk.
- ^ Effects of asymmetric dimethylarginine (ADMA) infusion in humans.
- ^ Kielstein JT, et al. Cardiovascular effects of systemic nitric oxide synthase inhibition with asymmetrical dimethylarginine in humans. Circulation. (2004)
- ^ a b Cooke JP. Asymmetrical dimethylarginine: the Uber marker. Circulation. (2004)
- ^ Leiper JM, et al. Identification of two human dimethylarginine dimethylaminohydrolases with distinct tissue distributions and homology with microbial arginine deiminases. Biochem J. (1999)
- ^ Jacobi J, et al. Overexpression of dimethylarginine dimethylaminohydrolase reduces tissue asymmetric dimethylarginine levels and enhances angiogenesis. Circulation. (2005)
- ^ Stühlinger MC, et al. Homocysteine impairs the nitric oxide synthase pathway: role of asymmetric dimethylarginine. Circulation. (2001)
- ^ Drexler H, et al. Correction of endothelial dysfunction in coronary microcirculation of hypercholesterolaemic patients by L-arginine. Lancet. (1991)
- ^ Ito A, et al. Novel mechanism for endothelial dysfunction: dysregulation of dimethylarginine dimethylaminohydrolase. Circulation. (1999)
- ^ Lin KY, et al. Impaired nitric oxide synthase pathway in diabetes mellitus: role of asymmetric dimethylarginine and dimethylarginine dimethylaminohydrolase. Circulation. (2002)
- ^ Willoughby DS, et al. Effects of 7 days of arginine-alpha-ketoglutarate supplementation on blood flow, plasma L-arginine, nitric oxide metabolites, and asymmetric dimethyl arginine after resistance exercise. Int J Sport Nutr Exerc Metab. (2011)
- ^ a b c d Schwedhelm E, et al. Pharmacokinetic and pharmacodynamic properties of oral L-citrulline and L-arginine: impact on nitric oxide metabolism. Br J Clin Pharmacol. (2008)
- ^ Ochiai M, et al. Short-term effects of L-citrulline supplementation on arterial stiffness in middle-aged men. Int J Cardiol. (2012)
- ^ Bode-Böger SM, et al. L-arginine induces nitric oxide-dependent vasodilation in patients with critical limb ischemia. A randomized, controlled study. Circulation. (1996)
- ^ Sydow K, et al. Central role of mitochondrial aldehyde dehydrogenase and reactive oxygen species in nitroglycerin tolerance and cross-tolerance. J Clin Invest. (2004)
- ^ Witte DR, et al. Measurement of flow-mediated dilatation of the brachial artery is affected by local elastic vessel wall properties in high-risk patients. Atherosclerosis. (2005)
- ^ Lind L. Arterial compliance influences the measurement of flow-mediated vasodilation, but not acetylcholine-mediated forearm blood flow. The Prospective Investigation of the Vasculature in Uppsala Seniors (PIVUS) study. Atherosclerosis. (2007)
- ^ a b Vasilijevic A, et al. Beneficial effects of L-arginine nitric oxide-producing pathway in rats treated with alloxan. J Physiol. (2007)
- ^ Méndez JD, Hernández Rde H. L-arginine and polyamine administration protect beta-cells against alloxan diabetogenic effect in Sprague-Dawley rats. Biomed Pharmacother. (2005)
- ^ a b Mohan IK, Das UN. Effect of L-arginine-nitric oxide system on chemical-induced diabetes mellitus. Free Radic Biol Med. (1998)
- ^ Lindsay RM, et al. N omega-nitro-L-arginine methyl ester reduces the incidence of IDDM in BB/E rats. Diabetes. (1995)
- ^ Kaneto H, et al. Apoptotic cell death triggered by nitric oxide in pancreatic beta-cells. Diabetes. (1995)
- ^ DiMagno MJ, et al. Secretagogue-stimulated pancreatic secretion is differentially regulated by constitutive NOS isoforms in mice. Am J Physiol Gastrointest Liver Physiol. (2004)
- ^ a b c Monti LD, et al. Effect of a long-term oral l-arginine supplementation on glucose metabolism: a randomized, double-blind, placebo-controlled trial. Diabetes Obes Metab. (2012)
- ^ Tang WH, et al. Diminished global arginine bioavailability and increased arginine catabolism as metabolic profile of increased cardiovascular risk. J Am Coll Cardiol. (2009)
- ^ Sourij H, et al. Arginine bioavailability ratios are associated with cardiovascular mortality in patients referred to coronary angiography. Atherosclerosis. (2011)
- ^ Jabłecka A, et al. The effect of oral L-arginine supplementation on fasting glucose, HbA1c, nitric oxide and total antioxidant status in diabetic patients with atherosclerotic peripheral arterial disease of lower extremities. Eur Rev Med Pharmacol Sci. (2012)
- ^ a b Álvares TS, et al. L-Arginine as a potential ergogenic aid in healthy subjects. Sports Med. (2011)
- ^ Long JH, et al. Arginine supplementation induces myoblast fusion via augmentation of nitric oxide production. J Muscle Res Cell Motil. (2006)
- ^ Maxwell AJ, et al. L-arginine enhances aerobic exercise capacity in association with augmented nitric oxide production. J Appl Physiol. (2001)
- ^ Schaefer A, et al. L-arginine reduces exercise-induced increase in plasma lactate and ammonia. Int J Sports Med. (2002)
- ^ Wax B, et al. Acute L-arginine alpha ketoglutarate supplementation fails to improve muscular performance in resistance trained and untrained men. J Int Soc Sports Nutr. (2012)
- ^ Abel T, et al. Influence of chronic supplementation of arginine aspartate in endurance athletes on performance and substrate metabolism – a randomized, double-blind, placebo-controlled study. Int J Sports Med. (2005)
- ^ Colombani PC, et al. Chronic arginine aspartate supplementation in runners reduces total plasma amino acid level at rest and during a marathon run. Eur J Nutr. (1999)
- ^ McConell GK. Effects of L-arginine supplementation on exercise metabolism. Curr Opin Clin Nutr Metab Care. (2007)
- ^ McKnight JR, et al. Beneficial effects of L-arginine on reducing obesity: potential mechanisms and important implications for human health. Amino Acids. (2010)
- ^ a b c d e Zajac A, et al. Arginine and ornithine supplementation increases growth hormone and insulin-like growth factor-1 serum levels after heavy-resistance exercise in strength-trained athletes. J Strength Cond Res. (2010)
- ^ a b c d Kanaley JA. Growth hormone, arginine and exercise. Curr Opin Clin Nutr Metab Care. (2008)
- ^ Oral arginine attenuates the growth hormone response to resistance exercise.
- ^ a b Marcell TJ, et al. Oral arginine does not stimulate basal or augment exercise-induced GH secretion in either young or old adults. J Gerontol A Biol Sci Med Sci. (1999)
- ^ a b Borst SE, Millard WJ, Lowenthal DT. Growth hormone, exercise, and aging: the future of therapy for the frail elderly. J Am Geriatr Soc. (1994)
- ^ a b Fogelholm GM, et al. Low-dose amino acid supplementation: no effects on serum human growth hormone and insulin in male weightlifters. Int J Sport Nutr. (1993)
- ^ Veldhuis JD, Bowers CY. Regulated recovery of pulsatile growth hormone secretion from negative feedback: a preclinical investigation. Am J Physiol Regul Integr Comp Physiol. (2011)
- ^ Veldhuis JD, et al. Neurophysiological regulation and target-tissue impact of the pulsatile mode of growth hormone secretion in the human. Growth Horm IGF Res. (2001)
- ^ Besset A, et al. Increase in sleep related GH and Prl secretion after chronic arginine aspartate administration in man. Acta Endocrinol (Copenh). (1982)
- ^ Barbul A, et al. Arginine enhances wound healing and lymphocyte immune responses in humans. Surgery. (1990)
- ^ Shi HP, et al. Supplemental L-arginine enhances wound healing in diabetic rats. Wound Repair Regen. (2003)
- ^ Debats IB, et al. Role of arginine in superficial wound healing in man. Nitric Oxide. (2009)
- ^ Shi HP, et al. Supplemental dietary arginine enhances wound healing in normal but not inducible nitric oxide synthase knockout mice. Surgery. (2000)
- ^ Shi HP, et al. Effect of supplemental ornithine on wound healing. J Surg Res. (2002)
- ^ Campbell B, et al. Pharmacokinetics, safety, and effects on exercise performance of L-arginine alpha-ketoglutarate in trained adult men. Nutrition. (2006)
- ^ Cynober L, et al. Action of ornithine alpha-ketoglutarate, ornithine hydrochloride, and calcium alpha-ketoglutarate on plasma amino acid and hormonal patterns in healthy subjects. J Am Coll Nutr. (1990)
- ^ a b c Moinard C, et al. Dose-ranging effects of citrulline administration on plasma amino acids and hormonal patterns in healthy subjects: the Citrudose pharmacokinetic study. Br J Nutr. (2008)
- ^ Rougé C, et al. Manipulation of citrulline availability in humans. Am J Physiol Gastrointest Liver Physiol. (2007)
- ^ Thibault R, et al. Oral citrulline does not affect whole body protein metabolism in healthy human volunteers: results of a prospective, randomized, double-blind, cross-over study. Clin Nutr. (2011)
- ^ Sureda A, et al. L-citrulline-malate influence over branched chain amino acid utilization during exercise. Eur J Appl Physiol. (2010)
- ^ Isidori A, Lo Monaco A, Cappa M. A study of growth hormone release in man after oral administration of amino acids. Curr Med Res Opin. (1981)
- ^ Shao A, Hathcock JN. Risk assessment for the amino acids taurine, L-glutamine and L-arginine. Regul Toxicol Pharmacol. (2008)
- ^ Hellier MD, Holdsworth CD, Perrett D. Dibasic amino acid absorption in man. Gastroenterology. (1973)
- ^ Izzo AA, Mascolo N, Capasso F. Nitric oxide as a modulator of intestinal water and electrolyte transport. Dig Dis Sci. (1998)